Literature DB >> 22743035

Soluble mediators of inflammation in HIV and their implications for therapeutics and vaccine development.

Sheila M Keating1, Evan S Jacobs, Philip J Norris.   

Abstract

From early in the HIV epidemic it was appreciated that many inflammatory markers such as neopterin and TNF-α were elevated in patients with AIDS. With the advent of modern technology able to measure a broad array of cytokines, we now know that from the earliest points of infection HIV induces a cytokine storm. This review will focus on how cytokines are disturbed in HIV infection and will explore potential therapeutic uses of cytokines. These factors can be used directly as therapy during HIV infection, either to suppress viral replication or prevent deleterious immune effects of infection, such as CD4+ T cell depletion. Cytokines also show great promise as adjuvants in the development of HIV vaccines, which would be critical for the eventual control of the epidemic.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22743035      PMCID: PMC3418433          DOI: 10.1016/j.cytogfr.2012.05.006

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  198 in total

1.  Analysis of the effect of highly active antiretroviral therapy during acute HIV-1 infection on HIV-specific CD4 T cell functions.

Authors:  Christine A Jansen; Iris M De Cuyper; Radjin Steingrover; Suzanne Jurriaans; Sanjay U C Sankatsing; Jan M Prins; Joep M A Lange; Debbie van Baarle; Frank Miedema
Journal:  AIDS       Date:  2005-07-22       Impact factor: 4.177

Review 2.  Interleukin-15 biology and its therapeutic implications in cancer.

Authors:  Jason C Steel; Thomas A Waldmann; John C Morris
Journal:  Trends Pharmacol Sci       Date:  2011-10-25       Impact factor: 14.819

3.  Augmentation of cell-mediated immunotherapy against herpes simplex virus by interleukins: comparison of in vivo effects of IL-2 and IL-7 on adoptively transferred T cells.

Authors:  P Wiryana; T Bui; C R Faltynek; R J Ho
Journal:  Vaccine       Date:  1997-04       Impact factor: 3.641

4.  IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine.

Authors:  K Q Xin; K Hamajima; S Sasaki; T Tsuji; S Watabe; E Okada; K Okuda
Journal:  Vaccine       Date:  1999-02-26       Impact factor: 3.641

5.  Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response.

Authors:  Béatrice Jacquelin; Véronique Mayau; Brice Targat; Anne-Sophie Liovat; Désirée Kunkel; Gaël Petitjean; Marie-Agnès Dillies; Pierre Roques; Cécile Butor; Guido Silvestri; Luis D Giavedoni; Pierre Lebon; Françoise Barré-Sinoussi; Arndt Benecke; Michaela C Müller-Trutwin
Journal:  J Clin Invest       Date:  2009-12       Impact factor: 14.808

6.  Qualitative immune modulation by interleukin-2 (IL-2) adjuvant therapy in immunological non responder HIV-infected patients.

Authors:  Francesca Sabbatini; Alessandra Bandera; Giulio Ferrario; Daria Trabattoni; Giulia Marchetti; Fabio Franzetti; Mario Clerici; Andrea Gori
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

7.  Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and D-dimer that are not associated with plasma HIV-RNA levels.

Authors:  Brian O Porter; Jean Shen; Joseph A Kovacs; Richard T Davey; Catherine Rehm; Jay Lozier; Gyorgy Csako; Khanh Nghiem; Rene Costello; Henry Clifford Lane; Irini Sereti
Journal:  AIDS       Date:  2009-09-24       Impact factor: 4.177

8.  Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial.

Authors:  Brian O Porter; Kara B Anthony; Jean Shen; Barbara Hahn; Chris E Keh; Frank Maldarelli; William C Blackwelder; Henry Clifford Lane; Joseph A Kovacs; Richard T Davey; Irini Sereti
Journal:  AIDS       Date:  2009-01-14       Impact factor: 4.177

9.  High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells.

Authors:  Paolo Serafini; Rebecca Carbley; Kimberly A Noonan; Gladys Tan; Vincenzo Bronte; Ivan Borrello
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

10.  The relation between symptoms, viral load, and viral load set point in primary HIV infection.

Authors:  Colleen F Kelley; Jason D Barbour; Frederick M Hecht
Journal:  J Acquir Immune Defic Syndr       Date:  2007-08-01       Impact factor: 3.731

View more
  17 in total

1.  Tumor necrosis factor α is associated with viral control and early disease progression in patients with HIV type 1 infection.

Authors:  Sagar A Vaidya; Christian Korner; Michael N Sirignano; Molly Amero; Sue Bazner; Jenna Rychert; Todd M Allen; Eric S Rosenberg; Ronald J Bosch; Marcus Altfeld
Journal:  J Infect Dis       Date:  2014-03-31       Impact factor: 5.226

2.  Replicative fitness of transmitted HIV-1 drives acute immune activation, proviral load in memory CD4+ T cells, and disease progression.

Authors:  Daniel T Claiborne; Jessica L Prince; Eileen Scully; Gladys Macharia; Luca Micci; Benton Lawson; Jakub Kopycinski; Martin J Deymier; Thomas H Vanderford; Krystelle Nganou-Makamdop; Zachary Ende; Kelsie Brooks; Jianming Tang; Tianwei Yu; Shabir Lakhi; William Kilembe; Guido Silvestri; Daniel Douek; Paul A Goepfert; Matthew A Price; Susan A Allen; Mirko Paiardini; Marcus Altfeld; Jill Gilmour; Eric Hunter
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-17       Impact factor: 11.205

3.  Elevated indoleamine-2,3-dioxygenase enzyme activity in a novel mouse model of HIV-associated atherosclerosis.

Authors:  Alison C Kearns; Stephani Velasquez; Fengming Liu; Shen Dai; Yong Chen; Gabrielle Lehmicke; Jennifer Gordon; Jay Rappaport; Xuebin Qin
Journal:  AIDS       Date:  2019-08-01       Impact factor: 4.177

Review 4.  Innate and Adaptive Immune Regulation During Chronic Viral Infections.

Authors:  Elina I Zuniga; Monica Macal; Gavin M Lewis; James A Harker
Journal:  Annu Rev Virol       Date:  2015-09-02       Impact factor: 10.431

Review 5.  Aging of the human innate immune system in HIV infection.

Authors:  Heidi J Zapata; Albert C Shaw
Journal:  Curr Opin Immunol       Date:  2014-07-02       Impact factor: 7.486

Review 6.  Mucosal immunology of HIV infection.

Authors:  Huanbin Xu; Xiaolei Wang; Ronald S Veazey
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

7.  Plasma monocyte chemoattractant protein-1 and tumor necrosis factor-α levels predict the presence of coronary artery calcium in HIV-infected individuals independent of traditional cardiovascular risk factors.

Authors:  Cecilia M Shikuma; Jason D Barbour; Lishomwa C Ndhlovu; Sheila M Keating; Philip J Norris; Matthew Budoff; Nisha Parikh; Todd Seto; Louie Mar A Gangcuangco; Debra Ogata-Arakaki; Dominic Chow
Journal:  AIDS Res Hum Retroviruses       Date:  2013-09-21       Impact factor: 2.205

8.  Continuous Antigenic Stimulation of DO11.10 TCR Transgenic Mice in the Presence or Absence of IL-1β: Possible Implications for Mechanisms of T Cell Depletion in HIV Disease.

Authors:  Kristin Ladell; Mette D Hazenberg; Mark Fitch; Claire Emson; Bridget K McEvoy-Hein Asgarian; Jeff E Mold; Corey Miller; Robert Busch; David A Price; Marc K Hellerstein; Joseph M McCune
Journal:  J Immunol       Date:  2015-09-28       Impact factor: 5.422

9.  HIV-1 Tat protein induces PD-L1 (B7-H1) expression on dendritic cells through tumor necrosis factor alpha- and toll-like receptor 4-mediated mechanisms.

Authors:  Rémi Planès; Lbachir BenMohamed; Kaoutar Leghmari; Pierre Delobel; Jacques Izopet; Elmostafa Bahraoui
Journal:  J Virol       Date:  2014-04-02       Impact factor: 5.103

10.  Distinct cytokine/chemokine network in semen and blood characterize different stages of HIV infection.

Authors:  Christophe Vanpouille; Andrea Introini; Sheldon R Morris; Leonid Margolis; Eric S Daar; Michael P Dube; Susan J Little; David M Smith; Andrea Lisco; Sara Gianella
Journal:  AIDS       Date:  2016-01       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.